Literature DB >> 19652932

Combined radiotherapy and indomethacin for the prevention of heterotopic ossification after total hip arthroplasty.

Emilios E Pakos1, Kosmas S Stafilas, Pericles G Tsekeris, Aggelos N Politis, Gregory Mitsionis, Theodore A Xenakis.   

Abstract

BACKGROUND AND
PURPOSE: :Heterotopic ossification (HO) is a frequent complication following total hip arthroplasty. The aim of this study was to evaluate the efficacy of combined radiotherapy and indomethacin as compared to indomethacin alone for the prevention of HO after hip arthroplasty. PATIENTS AND METHODS: 96 patients were prospectively enrolled to receive either a single dose of postoperative radiotherapy of 7.0 Gy and indomethacin for the first 15 postoperative days or indomethacin alone for the same period. A historical group of 50 patients that received indomethacin alone served as control. Primary endpoint was the radiographic evidence of HO at 6 months. Secondary endpoints were the evaluation of factors related to HO development, side effects from each treatment, and group differences in the clinical assessment with the Merle d'Aubigné Score.
RESULTS: Four patients in the combined-therapy group developed HO compared to 13 patients in the indomethacin group (p < 0.05) and 13 patients in the historical group (p < 0.05). One patient each in the combined group and the historical group developed Brooker III HO (nonsignificant difference). Duration of surgery and congenital hip disease were associated with HO development in the indomethacin groups, while age and congenital hip disease showed such an association in the combined-therapy group. The side effects and mean Merle d'Aubigné Score did not differ significantly between the three groups.
CONCLUSION: Combined radiotherapy and indomethacin was more efficacious in preventing HO after total hip arthroplasty compared to indomethacin alone and should be considered for future investigation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19652932     DOI: 10.1007/s00066-009-1954-3

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  44 in total

Review 1.  Heterotopic ossification after hip and knee arthroplasty: risk factors, prevention, and treatment.

Authors:  Richard Iorio; William L Healy
Journal:  J Am Acad Orthop Surg       Date:  2002 Nov-Dec       Impact factor: 3.020

2.  The efficacy of 500 CentiGray radiation in the prevention of heterotopic ossification after total hip arthroplasty: a prospective, randomized, pilot study.

Authors:  Douglas E Padgett; Keith G Holley; Marilyn Cummings; Aaron G Rosenberg; Dale R Sumner; Dean Conterato; Jorge O Galante
Journal:  J Arthroplasty       Date:  2003-09       Impact factor: 4.757

Review 3.  Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty.

Authors:  M Fransen; B Neal
Journal:  Cochrane Database Syst Rev       Date:  2004

4.  Selective COX-2 inhibitor versus indomethacin for the prevention of heterotopic ossification after hip replacement: a double-blind randomized trial of 100 patients with 1-year follow-up.

Authors:  Josef G Grohs; Maximilian Schmidt; Axel Wanivenhaus
Journal:  Acta Orthop       Date:  2007-02       Impact factor: 3.717

5.  Randomized trial comparing early postoperative irradiation vs. the use of nonsteroidal antiinflammatory drugs for prevention of heterotopic ossification following prosthetic total hip replacement.

Authors:  O Kölbl; D Knelles; T Barthel; U Kraus; M Flentje; J Eulert
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-12-01       Impact factor: 7.038

Review 6.  Heterotopic ossification: a review.

Authors:  Luc Vanden Bossche; Guy Vanderstraeten
Journal:  J Rehabil Med       Date:  2005-05       Impact factor: 2.912

7.  The influence of heterotopic ossification on functional status of hip joint following total hip arthroplasty.

Authors:  Fabian Pohl; Julia Seufert; Annette Tauscher; Harald Lehmann; Hans-Werner Springorum; Michael Flentje; Oliver Koelbl
Journal:  Strahlenther Onkol       Date:  2005-08       Impact factor: 3.621

8.  Risk factors for heterotopic ossification in total hip arthroplasty.

Authors:  S Eggli; A Woo
Journal:  Arch Orthop Trauma Surg       Date:  2001-10       Impact factor: 3.067

9.  Single-dose irradiation for the prevention of heterotopic ossification after total hip arthroplasty. A comparison of doses of five hundred and fifty and seven hundred centigray.

Authors:  W L Healy; T C Lo; A A DeSimone; B Rask; B A Pfeifer
Journal:  J Bone Joint Surg Am       Date:  1995-04       Impact factor: 5.284

10.  [Prevention of heterotopic ossification after THA with indomethacin: analysis of risk factors].

Authors:  H Zehetgruber; A Grübl; A Goll; E Schwameis; C Wurnig; A Giurea
Journal:  Z Orthop Ihre Grenzgeb       Date:  2005 Nov-Dec
View more
  4 in total

1.  [Heterotopic ossifications in major burn injuries : An interdisciplinary challenge].

Authors:  F Siemers; P L Stollwerck; J A Lohmeyer; T Namdar; P Mailänder
Journal:  Chirurg       Date:  2010-07       Impact factor: 0.955

2.  [The significance of radiation therapy for symptomatic vertebral hemangiomas (SVH)].

Authors:  Reinhard Heyd; M Heinrich Seegenschmiedt; Dirk Rades; Cornelia Winkler; Hans T Eich; Frank Bruns; Georg Gosheger; Normann Willich; Oliver Micke
Journal:  Strahlenther Onkol       Date:  2010-07-29       Impact factor: 3.621

Review 3.  Prophylactic Radiotherapy of Hip Heterotopic Ossification: A Narrative Mini Review.

Authors:  Massimiliano De Paolis; Alessio Giuseppe Morganti; Erika Galietta; Luca Gaiani; Claudio Giannini; Andrea Sambri; Milly Buwenge; Gabriella Macchia; Francesco Deodato; Savino Cilla; Lidia Strigari; Michele Fiore; Silvia Cammelli
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

Review 4.  Heterotopic Ossification: A Challenging Complication of Total Hip Arthroplasty: Risk Factors, Diagnosis, Prophylaxis, and Treatment.

Authors:  Paweł Łęgosz; Maciej Otworowski; Aleksandra Sibilska; Krzysztof Starszak; Daniel Kotrych; Adam Kwapisz; Marek Synder
Journal:  Biomed Res Int       Date:  2019-04-16       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.